Number enthusiasts may be looking to the new year with a touch of melancholy. Another perfect square like 2025 (45 2 = 2,025) ...

Abstract: In this paper, we propose an encrypted dynamic controller that executes an unlimited number of recursive homomorphic multiplications on a Ring Learning With Errors (Ring-LWE) based ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

To effectively use natural rubber (NR) in the rubber industry, it is essential to reduce its viscosity (or molecular weight) through a process known as NR mastication or breakdown, in order to achieve ...

Abstract: Information Extraction (IE) and Text Classification (CLS) serve as the fundamental pillars of NLU, with both disciplines relying on analyzing input sequences to categorize outputs into ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

A century ago, the strange behavior of atoms and elementary particles led physicists to formulate a new theory of nature. That theory, quantum mechanics, found immediate success, proving its worth ...

Recursion Pharmaceuticals remains a high-cash-burn, premium-valued biotech with unproven clinical success despite a recent 47% rally. RXRX's next 18 months are catalyst-rich, but key pipeline assets ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...